Background {#Sec1}
==========

The family *Herpesviridae* comprises a diverse group of viruses, which are divided into three subfamilies (*α*-, *β*- and *γ-herpesviridae*) \[[@CR1]\]. Most commonly, herpesvirus infection presents as a benign, self-limiting disease with a mild viraemia. Herpesvirus rarely causes widespread disseminated disease in the natural host, although cross-species transmission to non-reservoir hosts can also result in lethal infections \[[@CR2]\]. In general neonates and immune-compromised hosts are at higher risk of developing a fatal herpesvirus infection \[[@CR3], [@CR4]\].

The elephant endotheliotropic herpesvirus (EEHV) is a poorly characterized virus of elephants that was first observed in healthy wild African elephants (*Loxodonta africana*) by McCully et al. \[[@CR5]\] in 1971 and subsequently in Asian elephants (*Elephas maximus*) with no apparent disease \[[@CR6]\]. In 1990 the death of a 3-year old female Asian circus elephant was associated with herpesvirus by Ossent et al. \[[@CR7]\]. Pathologic changes in the capillary endothelial cells with herpetic inclusion bodies and weak cross-neutralization in serum neutralization tests with bovine herpesviruses suggested that the etiologic agent was a hitherto unidentified herpesvirus \[[@CR8], [@CR9]\], which was identified in 1999 \[[@CR10]\]. The disease has a sudden onset characterized by lethargy, oral ulcerations, edema in the skin of the head and proboscis, cyanosis of the tongue, decreased white blood cell and platelet count and massive internal hemorrhages, which lead to death within 12--72 h after onset of the symptoms. Phylogenetic analysis showed that EEHV is a distinct branch within the β-herpesviridae group, assigned as the new genus *Proboscivirus* \[[@CR11], [@CR12]\]. To date, as many as seven different genotypes of EEHV have been identified within this genus \[[@CR13]\]. However, xtensive evaluation of several subtypes indicated that EEHVs have a large genomic inversion of a 40-kb core segment that is distinct from the Roseoloviruses and all other β-herpesviruses. Furthermore, they encode α-herpesvirus-like genes that are absent in β-herpesviruses and contain 60 novel open reading frames not found in any other herpesvirus \[[@CR12], [@CR14]\]. These findings suggest that this particular virus is so different from other herpesviruses that it may be considered as a new herpesvirus subfamily \[[@CR12], [@CR13]\].

EEHV poses a threat to the conservation mission of zoos. Several studies have shown that DNAemia can be detected in Asian elephants before the onset of clinical signs and in elephants that do not display clinical signs using PCR techniques \[[@CR15]--[@CR19]\]. To date, this is the only option to monitor a complete herd, and only allows identification of animals with an active infection. Therefore, the detection of antibodies against EEHV likely offers a better strategy to determine which animals are carriers of EEHV. Ideally, antibody detection against the whole virus is preferable, but since the virus cannot be cultured *in vitro*, the best alternative is to use an immunodominant protein, such as glycoprotein B (gB), as an antigen. The viral envelope protein glycoprotein B of herpesviruses is involved in host cell entry and represents an important target of neutralizing antibodies in the host \[[@CR20], [@CR21]\]. In this study a serologic test based on the EEHV-gB antigen is described. This assay was used to assess seroprevalence against EEHV-gB in serum and heparin plasma samples from two large cohorts of European and North-American captive Asian elephants. These data are useful to link seroprevalence with EEHV virus detection by PCR methods and, at the end, may give better insight into EEHV dynamics within elephant populations.

Methods {#Sec2}
=======

Cloning, expression and large scale production of glycoprotein B {#Sec3}
----------------------------------------------------------------

The viral sequence of EEHV-1A glycoprotein B \[GenBank: AF411189\] \[[@CR22]\] comprising the start codon up to the transmembrane domain was synthesized (BaseClear, The Netherlands) and cloned, using XhoI/PstI restriction sites, into the multiple cloning site in frame with a C-terminal myc/^6^His tag, but in an alternative open reading frame (ORF) relative to the Shine Dalgarno ribosomal binding site, of the bacterial expression vector pTrcHis2A (Invitrogen). Induction of recombinant glycoprotein B expression was performed in *E.coli* Rosetta2(DE3)pLysS codon plus strain (Millipore). This strain supplies tRNAs for 7 rare codons (AGA, AGG, AUA, CUA, GGA, CCC, and CGG) in order to improve the expression of heterologous proteins.

A single colony transformed with the pTrcHis2A-gBmyc/his plasmid was inoculated into fresh LB medium containing 100 μg/ml ampicillin and 50 μg/ml chloramphenicol and grown overnight at 37 °C in a shaker incubator. The next day 2 l fresh LB medium without antibiotics was inoculated 1 in 100 with the pre-culture and grown in a shaker incubator at 37 °C to an OD~600~ \~ 0.6. The recombinant protein expression was induced by adding IPTG to an end concentration of 1 mM. The temperature was lowered to 25 °C for optimal recombinant protein expression.

Cells were harvested 4 h after induction and pelleted at 6000xG for 10 min in a Beckman Highspeed centrifuge using the JLA16.250 rotor. The supernatant was decanted and the cells were resuspended in native lysisbuffer (500 mM of NaCl, 50 mM phosphatebuffer (pH 8.0), 5 % v/v glycerol and 10 mM of Imidazole and protease inhibitors). Lysozyme was added to an end concentration of 1 mM and the cells were treated 30 min at 4 °C at continuous agitation. The cells were cracked by three freeze/thaw cycles and sonification with a microtip; 8 x 30s at 60 % on ice (Sonopulse HD2070, Bandelin, Germany). The lysate was cleared by ultracentrifugation for 2 h at 27.000 rpm in a Beckman Optima L-90 K ultracentrifuge using the SW32Ti rotor. A similar procedure was conducted with another pTrcHis2A vector encoding a 27 kD irrelevant ^6^His-tagged protein that was used as a negative control.

Purification of glycoprotein B {#Sec4}
------------------------------

The cleared lysate was loaded onto Ni-NTA resin (Superflow, IBA) which was preconditioned with water and 1x native lysisbuffer. Binding was performed overnight at +4 °C under continuous agitation. Next day, the resin was settled vertically and washed with 6 bed volumes of lysisbuffer containing 20 mM of Imidazole. Thereafter, the bound recombinant protein was eluted with 4 bed volumes of elution buffer (500 mM of NaCl, 50 mM phosphate buffer (pH 8.0), 5 % v/v glycerol and 300 mM of Imidazole). Subsequently, salts were removed by dialysis in a Slide-a-Lyzer cassette (3,500 MWCO, 3--12 ml capacity, ThermoScientific) for 48 h at +4 °C. The dialysis buffer (PBS complemented with 0.1 M NaCl and 5 % v/v glycerol) was refreshed three times. After dialysis the recombinant protein content was analyzed for protein concentration (BCA assay, ThermoScientific) and Western Blot. A second round of purification was performed by fast protein liquid chromatography (FPLC) with a 1 ml volume HisTrap-HP^TM^ column (GE Health Care life sciences) with a pressure flow of 0.15 ml/min. The his-tagged proteins were eluted from the column with 10 column volumes (CV) of a linear gradient ranging from 50 mM Imidazole up to 500 mM Imidazole in 0.5 ml aliquots. These were analyzed by Western blot and the eluates containing the his-tagged proteins were subsequently pooled and dialyzed as described above.

Rabbit anti-EEHV glycoprotein B serum {#Sec5}
-------------------------------------

Five peptide sequences (QDLTVTVSTKKKTF, YNGQNNKKFSEPSTK, VLDTDSDKKNYSYMS, ANVTSRRRKRDANTA and EPSTKFKVYKDYERLQ) derived from the amino acid sequence of glycoprotein B of EEHV1A \[GenBank: AF411189\] were synthesized and coupled to LPH (Limulus polyphemus hemocyanin) carrier protein. Ten rabbits (*n* = 2 Zimmerman rabbits/peptide) were immunized six times intramuscularly with 10 μg of the respective peptides. Final bleeding was at day 133 after the first vaccination. The polyclonal rabbit sera were produced by Biogenes GmbH (Germany) according to European law on animal welfare. All rabbit sera were highly reactive against the respective peptide as tested in a peptide ELISA assay.

Immunodetection of recombinant glycoprotein B {#Sec6}
---------------------------------------------

Recombinant glycoprotein B antigen was analyzed by separation of small samples from the purification process on a 10 % SDS-PAGE gel (BioRad Laboratories) and separated products were subsequently transferred to PVDF membrane (Immobilon, Millipore). Gels were run in duplicate; one was Coomassie Blue stained for total protein and the duplicate was analyzed with Western blot using an anti-^6^His tag mouse monoclonal antibody (Clontech). As a secondary antibody goat anti-mouse IRdye680 (Licor) was used.

Rabbit serum reactivity with recombinant glycoprotein B was detected with Western Blot by incubating the membranes with rabbit serum (1:400 dilution) followed by detection with goat-anti-rabbit IRdye680 (Licor). Similar strategy was done for elephant serum (1:1000 dilution), but primary antibody was detected with rabbit-anti Asian elephant IgG (1:1000 dilution). Sera of rabbits as well as elephants were pre-incubated in buffer containing *E.coli* lysate (\~3 μg/ml) for 1 h at room temperature in order to reduce possible *E.coli* reactivity. The signal of the conjugate was detected with the Licor Odyssey scanner (Licor).

Glycoprotein B specific capture ELISA {#Sec7}
-------------------------------------

To avoid non-specific reaction against *E.coli* contaminants which co-purified with the ^6^His-tagged EEHV gB antigen during Ni-NTA purification an optimal concentration of 100 ng/well of mouse-anti ^6^His antibody (ClonTech) as a capture antibody was coated in high binding 96-well microtiterplate (Costar). The microtiter plates were blocked with 100 μl/well of PBS containing 2 % w/v BSA in PBS for one hour at 37 °C and washed. All washing steps were performed three times with 200 μl of wash buffer (PBS + 0.05 % v/v Tween20). To determine the optimal antigen concentration for use in the ELISA, the gB antigen was diluted two-fold starting at 2400 ng per well. A pool of rabbit sera was used as anti-gB positive serum.

The purified EEHV-gB antigen was diluted in PBS containing 0.1 % Triton-X to a concentration of 750 ng/well and bound to the capture antibody for 1 h at 37 °C.

After washing, primary incubation was performed with 100 μl/well diluted (1:100 and 1:200) elephant serum in ELISA buffer containing PBS, 0.2 % BSA, 0.1 % non-fat dried powder milk and 3 % w/v NaCl and incubated for one hour at 37 °C. After washing, elephant specific IgG's bound to glycoprotein B were detected by incubation with 100 μl/well of rabbit anti-elephant IgG (1:1000 diluted in ELISA buffer) for one hour at 37 °C followed by an incubation step with swine anti-rabbit IgG HRPO conjugate (1:1000 diluted in ELISA buffer). After washing 100 μl/well 1xTMB substrate (KPL laboratories) was added, incubated for 10 min at room temperature. The reaction was stopped by adding 100 μl 0.5 M H~2~SO~4~ per well. The absorbance (OD) was measured at 450 nm with 620 nm reference filter (A~450/620~) on a 96-well plate spectrophotometer (Tecan).

Study cohort in Europe/USA {#Sec8}
--------------------------

The elephants in this study were kept in zoos as part of the European Endangered Species Program (EEP, Europe) and the Species Survival Program (SSP,USA). Within these programs elephants are trained to allow voluntarily blood collection for several reasons: monitoring health parameters, monitoring reproduction parameters and providing (retrospective) data for new diagnostic technologies for diseases that may threaten their health. The use of banked elephant blood samples for a retrospective research study falls within the law. All participating zoos reviewed and approved the research proposal for this study and allowed the use of their banked elephant blood samples.

All elephants in the study were Asian elephants; Table [1](#Tab1){ref-type="table"} (Asian elephants located in Europe) and 2 (Asian elephants located in North America) summarize the age, sex, and clinical status of elephants which will be discussed in detail in this study. All participating zoos reviewed and approved the research described in this study. Initially, 831 serum or heparin plasma samples of 125 Asian elephants located in 14 European zoos were tested for validation of the capture ELISA test. The cut-off value was calculated as a mean OD of 37 samples of 19 animals which scored consistently on the base line level of the test.Table 1Age, sex, and clinical status of elephants in the study cohort of European zoosZooAnimalSexBornStatusAgeSerostatusSample \#PeriodPCR detectionDetection siteClinical signsRemark1AFcaptivealive44pos\>502002--2014EEHV1B - 2007/2008O/Vsubclinicalref \[[@CR17]\]1A1Fcaptivealive14pos\>502002--2014EEHV1B - 2007Osubclinicalref \[[@CR17]\]1CFwildalive28border\>502002--2012EEHV1B - 2008Osubclinicalref \[[@CR17]\]1DFcaptivealive12ND\>502013--2014EEHV1B - 2008Osubclinicalref \[[@CR17]\]1EMcaptivealive17pos22013--2014EEHV1 - 2014TW/Csubclinical2AMcaptivealive23ND\>502006--2013not detected2BFwildalive31border\>502006--2013EEHV5 -2011TWsubclinical2B1Mcaptivealive10pos40--502006--2011EEHV1A - 2008/2011WBsubclinical2B2Mcaptivedead1pos32006--2013EEHV1A - 2009necropsyfatality2B3Mcaptivealive3pos82012--2013EEHV1 - 2013WBclinically ill 20132CFwildalive33ND40--502006--2013EEHV1A - 2011TWsubclinicalnegative study control2DFwildalive33border40--502006--2013not detectedndhealthy2EFcaptivealive32pos\>502006--2013EEHV1A - 2011TWsubclinical2E1Fcaptivedead2pos32006EEHV1B - 2006necropsyfatalityref \[[@CR14]\]2E2Fcaptivedead2pos32006--2013EEHV1A - 2009necropsyfatality2E3Fcaptivealive5pos\>502006--2013EEHV1A - 2011TWsubclinical2FFcaptivealive16ND\>502006--2013EEHV1A - 2011U/Vsubclinical2F1Mcaptivealive5pos202011--2013EEHV1A - 2011TWsubclinical3AFcaptivealive19ND40--502007--2012not available3BFwildalive30pos40--502006--2012not available3CFwildalive30border202012not available3C1Fcaptivealive16border202012not available4AMcaptivealive9pos22007--2014not donepositive study control5AFwildalive29pos12002not donepositive study controlZoos are numbered, elephants are indicated with a letter and subsequent numbers describe maternal offspring*ND*, not detectable*TW*, trunk wash*C*, conjunctiva*U*, urine*O*, oral lesion*WB*, whole blood*V*, vulva

Three European zoos (Zoo 1, 2 and 3) provided Asian elephant serum or plasma samples for a longitudinal seroprevalence study ranging from 250 up to 600 days for multiple animals in their herds. Moreover, the samples from Zoo 1 and 2 (including trunkwash and conjunctiva swabs) were also analyzed for EEHV presence by qPCR.

In the USA cohort 476 Asian elephant samples were tested from 63 animals in 17 zoos in the period 2006 until 2012 with a six month interval.

All samples were tested in 1:100 and 1:200 dilutions and the signal to background OD was calculated for both dilutions. A sample was considered positive when both dilutions produced ODs 3 times of the background OD and undetectable when both dilutions produced less than 2 times the background OD. A sample was considered as borderline when one or both dilutions measured an OD between 2--3 times the background OD values.

An animal was considered to be seropositive when all analyzed samples scored positive with an occasional borderline score. An animal was considered borderline seropositive when the majority of its samples scored borderline. An animal was considered undetectable when all of its samples were undetectable.

Results {#Sec9}
=======

Expression and purification of EEHV glycoprotein B {#Sec10}
--------------------------------------------------

Positioning of the EEHV-gB open reading frame (ORF) in an alternative position downstream of the Shine Dalgarno ribosomal binding site (RBS) severely reduced the expression levels of the recombinant EEHV-gB, but retained the recombinant protein in the soluble fraction and in its native conformation. Purification of the recombinant EEHV-gB was performed using nickel columns (Fig. [1](#Fig1){ref-type="fig"}). Full length EEHV-gB has an expected molecular size of 87 kD, and a band at this expected size was observed (Fig. [1b](#Fig1){ref-type="fig"}). Since the portion of recombinant gB protein in the *E.coli* lysate was low many native proteins of *E. coli* Rosetta2 that displayed affinity to nickel in the Immobilized Metal Affinity Chromatography (IMAC) were co-purified during Ni-NTA purification. Full length as well as many other molecular weight sizes, were detected by anti-^6^His-tag antibody detection on Western Blot. Western blot analysis with the EEHV-gB peptide specific rabbit (ANVTSRRRKRDANTA) serum showed more bands with different molecular weights compared to the pattern obtained with anti-his antibody (Fig. [2a](#Fig2){ref-type="fig"} and [b](#Fig2){ref-type="fig"}). Several specific smaller bands were also detected. An elephant serum, which did contain EEHV-gB specific antibodies, as detected with the described sandwich ELISA, did not recognize as many of the EEHV-gB fragments on Western blot (Fig. [2c](#Fig2){ref-type="fig"}). Since the double purified (Ni-NTA followed by FPLC Histrap) lost a portion of the full length EEHV-gB (Fig. [2a](#Fig2){ref-type="fig"}) the single Ni-NTA purified antigen was further used to develop an ELISA test.Fig. 1SDS-PAGE total protein analysis (panel **a**) and Western blot analysis with an anti-His monoclonal antibody (panel **b**) demonstrate the purification of full length EEHV-gBHis (\~87 kD) and several smaller fragments with a his-tag produced from the EEHV-gBHis open reading frame (lane EL, eluate). During purification a small portion of the recombinant protein is lost in the flow through of the NiNTA column (lane FT) and during the washing steps (lane W1-2, W3-4, W5-6). The empty vector does not yield any his-tagged proteins (lane UT). Lane M is the molecular weight markerFig. 2Western blot analysis of an irrelevant 27 kD his-tagged protein and (lane 1), single NiNTA purified EEHV-gBHis (lane 2) and double purified NiNTA/HisTrap FPLC (lane 3) with three different antisera. **a** Western blot with mouse monoclonal anti-His demonstrates the 27 kD His-tagged protein in lane 1 and the highly fragmented EEHV-gBHis in lane 2 and 3. Double purification results in loss of the full length EEHV-gBHis (lane 3). **b**The rabbit peptide (ANVTSRRRKRDANTA) EEHV-gB specific antiserum recognizes non-his tagged bands. **c** Serum of elephant 4A detects identical bands as the rabbit peptide specific serum in the EEHV-gBHis recombinant protein, except for the \~32 kD band which might be an *E.coli* background band (panel **b**)

Validation of an EEHV glycoprotein B specific capture ELISA {#Sec11}
-----------------------------------------------------------

To reduce aspecific *E.coli* protein reactivity (Fig. [3a](#Fig3){ref-type="fig"}) the ELISA assay was setup as a capture ELISA using a mouse-anti ^6^His monoclonal antibody. Pooled sera of rabbits immunized with EEHV-specific peptides were used as a positive control. Figure [3](#Fig3){ref-type="fig"} shows that 100 ng of the capture antibody reduces aspecific reactivity to an acceptable background level of an A~450/620~ of \~0.2. Subsequently, the capture ELISA was further validated with an antigen checkerboard titration to test its specificity with various irrelevant rabbit sera. The results in Fig. [4](#Fig4){ref-type="fig"} demonstrate a dose-related response only when EEHV-gB specific sera were used. Irrelevant rabbit antisera did not react with the antigen. To detect antibody reactivity in the linear range an optimum of 750 ng antigen/well was used in the ELISA, which was used to evaluate the elephant sera cohorts. Once the capture ELISA was developed with the EEHV-gB specific rabbit sera, a large panel of elephant sera was tested to screen for sera with specific reactivity. In total 831 serum or plasma samples of Asian elephants, representing 125 animals of 14 zoos were tested. Twenty-three animals from 7 zoos tested consistently positive (18 %), 24 animals of 5 zoos tested intermittently positive/borderline/undetectable (19 %) and 78 animals tested consistently undetectable (63 %). The test was repeated twice in separate experiments and the results were reproducible. We found three sera with extremely high reactivity in the capture ELISA (elephant 2B1, 4A and 5A respectively, Table [1](#Tab1){ref-type="table"}) and several non-reactive sera (lowest responder was elephant 2C). These elephant sera were used to test again the antigen dose and specificity (Fig. [5](#Fig5){ref-type="fig"}). The sera of elephant 2B1, 4A and 5A showed a dose-dependent reactivity whereas the serum from elephant 2C did not (Fig. [5a](#Fig5){ref-type="fig"}). Serial dilutions of serum of animal 5A (positive serum) and animal 2C (undetectable serum) on EEHV-gB antigen or an irrelevant ^6^His-tagged protein were used in the assay to test the specificity. Only the positive serum of animal 5A reacted in a dose-dependent manner with EEHV-gB antigen and not with the irrelevant antigen (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 3*E. coli* protein contamination in the purified antigen (Ag) induces background signal in an indirect ELISA (panel **a**). This background is reduced in a sandwich ELISA using a mouse monoclonal anti-his antibody as a capture antibody for the target antigen (panel **b**-**d**). Pooled EEHV-gB peptide specific rabbit serum was used in a 1:200 dilution. Panel A no capture antibody, panel B 100 ng capture antibody, panel **c** 200 ng capture antibody, panel D 300 ng capture antibodyFig. 4Specificity of the EEHV-gB sandwich ELISA was determined by antigen titration with the EEHV-gB peptide specific rabbit serum, one serum of an EEHV1 PCR positive elephant and two irrelevant rabbit sera. All sera were diluted 1:200 in ELISA bufferFig. 5Characterization of the sandwich ELISA with elephant sera. Elephant sera react in a dose-dependent manner as shown by antigen titration (panel **a**) and are specific for the EEHV-gB antigen only (panel **b**)

The majority of EEHV PCR positive elephants display EEHV specific antibodies {#Sec12}
----------------------------------------------------------------------------

For 36 animals (Table [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) EEHV PCR data was available, either from published data \[[@CR12], [@CR14], [@CR15], [@CR17], [@CR19], [@CR23], [@CR24]\] or personal communications. We compared these results with our ELISA results. Nineteen out of 25 PCR positive animals (76 %) displayed antibodies, of which 16 had significant antibody titers and three had borderline titers. However, in six out of 25 animals no EEHV specific antibodies could be detected (elephants 1D, 2C, 2 F, 6A, 6C, 6C1) while they had been tested positive with the EEHV specific PCR. Eight elephants displayed EEHV-gB specific antibodies, but never tested positive in a routine PCR (elephant 2D, 7A, 7B1, 7D, 7E, 9B1-1, 9C and 9D). Four animals were EEHV5 PCR positive of which three displayed antibodies against EEHV-gB.Table 2age, sex, and clinical EEHV status of elephants in the study cohort of USA zoosZooAnimalSexBornStatusAgeSerostatusSample \#PeriodPCR detectionDetection siteClinical signsRemark1AMwildalive50ND132006--2012EEHV5A (2011)TWsubclinical1BFwildalive46border132006--2012EEHV1B (2009)/EEHV5(2011)WBLethargicref \[[@CR23], [@CR24]\]1CFwildalive34ND92008--2012EEHV1A-(2009)/EEHV5B (2011)TWsubclinicalref \[[@CR15]\]1C1Mcaptivealive10ND92008--2012EEHV1A/EEHV1B/EEHV5BTW/WBsubclinicalref \[[@CR15], [@CR23]\]1C2Fcaptivealive4pos22012EEHV5A (2011)TWSubclinicalref \[[@CR15]\]2DFcaptivealive24pos132006--2012EEHV1A(2009)/EEHV1B (2010)TW/WB 2010Subclinicalref \[[@CR12], [@CR19], [@CR24]\]2D1Mcaptivealive5pos22010--2012EEHV5A (2011)TW/WBTemporal gland swellingref \[[@CR15]\]2AFwildalive44pos112006--2011not detected2BFwildalive44ND122006--2011not detected2B1Mcaptivealive22pos112006--2011not detected2CFwildalive44ND112006--2011not detectedref \[[@CR19]\]2C1Fcaptivealive8pos62009--2011EEHV1A (2010)/EEHV1B (2009)WB/TWsubclinical feb/dec 2009ref \[[@CR19]\]2DFwildalive35pos112006--2011not detected2EFcaptivealive18pos112006--2011not detected2E1Fcaptivealive8pos52009--2011EEHV1A/EEHV1B (2009)WB/TWclinically ill feb/dec 2009ref \[[@CR19]\]2AFwildalive45pos72006--2010not available2BFwildalive44pos72006--2010not available2B1Fcaptivealive16pos72006--2010not available3CFwilddead41border42006--2007not available3DFcaptivealive26pos72006--2010not available3AFwildalive48border102006--2011not done3BFwildalive41border92006--2011not done4B1Fcaptivealive22pos102006--2011not done5B1-1Fcaptivealive5pos12010not detected1CMcaptivealive17pos102006--2011not detected1DMcaptivealive16pos72006--2009not detectedZoos are numbered, elephants are indicated with a letter and subsequent numbers describe maternal offspring*ND*, not detectable*TW*, trunk wash*C*, conjunctiva*U*, urine*O*, oral lesion*WB*, whole blood*V*, vulva

Seroprevalence of a European study cohort {#Sec13}
-----------------------------------------

Three European zoos were approached to collaborate in our study; their animals are listed in Table [1](#Tab1){ref-type="table"} (zoo 1 to 3) and their Asian elephant sera collections were analyzed over a substantial period of time (600 days Zoo 1, 400 days Zoo 2 and 250 days Zoo 3). During the study period the animals of Zoo 1 and 2 were screened for EEHV virus presence in whole blood, trunk wash and conjunctiva swabs by either conventional or real time PCR. Figure [6](#Fig6){ref-type="fig"} displays the serostatus of these three herds; the observed patterns showed a rise-and-fall in signal to background ratios (thus, relative antibody quantity). A similar rise-and-fall pattern was observed for animals, which scored below the detection level. Additional clinical evaluations of the animals in this study can be found in (Additional file [1](#MOESM1){ref-type="media"}).Fig. 6Serostatus of three European zoos measured as the signal to background ratio over a period of time. Zoo 1 (panel **a**) was studied from October 2012 until April 2014. Zoo 2 (panel **b**) was studied from May 2012 until May 2013 and Zoo 3 (panel **c**) from January 2012 until September 2012. The arrow indicates a positive EEHV1 PCR of the trunk wash (animal 1A) or whole blood (animal 2B3). Elephants with non-detectable levels of EEHV antibodies are indicated in black, elephants with an alternating serostatus in orange and elephants with continuous anti-EEHV antibodies in red

Only two animals had a positive PCR in the study-period in either trunk wash (animal 1A) or whole blood (animal 2B3). As seen in Fig. [6a](#Fig6){ref-type="fig"} animal 1A was EEHV1 PCR positive in trunk wash on day 150 and, shortly afterwards, had elevated antibody titers up to 8 weeks after the PCR positive trunk wash. As shown in Fig. [6b](#Fig6){ref-type="fig"} calf 2B3 developed a DNAemia and clinical signs of EEHV disease on day 370 of the study period with typical EEHV clinical signs. However, this calf was already seropositive on day 90 of the study period. He survived this episode with supportive treatment and famciclovir administration. Eighteen days prior to disease onset his half-sister 2E3 showed a rise in antibody titers. Unfortunately no samples of the other herd members were available in this period of the study.

Discussion {#Sec14}
==========

To date, an accurate and dependable test to evaluate EEHV seroprevalence in Asian elephants has not been developed. In part, this is due to the inability to culture the virus *in vitro* and therefore whole virus is not available as the ideal antigen source for an ELISA. Production of recombinant proteins from one of the EEHV glycoproteins, like gB, has proven to be a major challenge. Here we describe a novel ELISA that specifically detects EEHV-gB antibodies circulating in Asian elephants. We were able to link seroprevalence to PCR detection of the EEHV in approximately 80 % animals. This novel assay will provide more insight into the epidemiology of this hitherto poorly understood virus.

The antigen expression, production and purification methods for fragmented EEHV-gB (genotype 1A) driven by a bacterial Shine Dalgarno promoter in an alternative open reading frame, yielded antigens for a sandwich ELISA specific for EEHV-gB. Incomplete EEHV-gB amino acid sequences were produced from the plasmid presumably due to programmed ribosomal frameshifting (PRF) and alternative translation initiation sites. PRF and alternative translation initiation are well-described phenomena \[[@CR25]--[@CR28]\] and can occur in prokaryotes, as well as in eukaryotes. PRF occurs when the ribosome encounters a so-called hungry codon (low level of acetylated tRNA) in its A-site followed by a slippery sequence in the P-site of the ribosomal complex. In our expression system, it is likely that the Shine Dalgarno sequence RBS initiates the overexpression of a short nonsense peptide of 36 amino acids thereby releasing the ribosomes quickly in order to re-initiate translation with a high likelihood to undergo PRF since this small ORF contains multiple hungry codons. As a side product, fragments of EEHV-gB specific sequences, either with or without a his-tag were made and confirmed by Western blot analysis. This suggested that the non-his-tagged fragments were co-purified during the purification process. EEHV-gB peptide specific rabbit sera were able to detect the antigen fragments, whereas positive elephant sera recognized fewer of these fragmented antigen products. It is likely that the majority of the anti-EEHV-gB antibodies in elephants recognize conformational epitopes, which are linearized in Western Blot. This is supported by the fact that the produced antigen was highly reactive in the sandwich ELISA test with the positive rabbit sera as well as many elephant sera and not with irrelevant sera. As a result, it is likely that this ELISA would fail to detect antibodies directed to those conformational epitopes of gB which do not form properly in the bacterial expression machinery. In this study no seronegative elephants were found. The background of the described assay was set up with sera of elephants, which were consistently found on the non-detectable range of the assay, but still \~0.1 OD higher than naïve rabbit serum. This test was developed with a capture antibody, which did not completely reduce the background to an OD of 0. Therefore, it is highly likely that the cut-off value was leveled unrealistically high. In the study cohort we found several seropositive elephants, which were routinely diagnosed with other subtypes than EEHV1A by PCR. The obtained data suggest that this test may be able to detect antibodies against gB from EEHV subtypes other than EEHV1A; at least EEHV1B and EEHV5. Divergence on the amino acid level of the glycoprotein B of the subtypes EEHV ranges from 11 % (EEHV1A vs EEHV1B) up to 21 % (EEHV1A vs EEHV5) \[[@CR23]\]. However, we cannot exclude that these animals did had an EEHV1A co-infection as well. It is interesting to speculate that genetic background plays a role in susceptibility to develop severe disease. However, better designed study cohorts, which include serology as well as PCR detection of the virus are required in order to address the question whether the host genetic background has a major role in fatal EEHV disease.

Conclusion {#Sec15}
==========

We have shown that it is possible to express the gB of EEHV in a bacterial system by using alternative translation upstream of the Shine Dalgarno sequence. Further, our results and those of recent reports \[[@CR15], [@CR17], [@CR19], [@CR29]\] demonstrate that EEHV prevalence in captive born as well as wild-born elephants (as measured by virus detection with PCR techniques in whole blood and trunk secretions) is much higher than initially anticipated. These studies underline that elephants may be the natural host of EEHV that, in general, does not cause major disease. The methodology and data presented in this article give a novel insight into the EEHV1 seroprevalence in Asian elephants. As expected, a large portion of elephants showed antibodies against EEHV, but not all. Additionally, the serostatus of elephants within a herd may vary from non-detectable up to high titers.

Additional file {#Sec16}
===============

Additional file 1:**Supplementary information.** (DOCX 125 kb)
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:   Bicinchoninic acid

BSA

:   Bovine serum albumin

CV

:   Column volume

EEHV

:   Elephant endotheliotropic herpes virus

EEP

:   Endangered species program

ELISA

:   Enzyme linked immunosorbent assay

EM

:   *Elephas maximus*

FPLC

:   Fast protein liquid chromatography

gB

:   Glycoprotein B

HPRO

:   Horse radish peroxidase

IMAC

:   Immobilized metal affinity chromatography

IPTG

:   Isopropyl β-D-thiogalactoside

LA

:   *Loxodonta africana*

LB

:   Luria Bertani broth

LPH

:   Limulus polyphemus hemocyanin

Ni-NTA

:   Nickel nitrilotriacetic acid

nm

:   Nanometer

OD

:   Optical density

ORF

:   Open reading frame

PBS

:   Phosphate buffered saline

PCR

:   Polymerase chain reaction

PRF

:   Programmed ribosomal frameshifting

PVDF

:   Polyvinylidene difluoride

qPCR

:   Quantative polymerase chain reaction

RBS

:   Ribosomal binding site

SDS-PAGE

:   Sodium dodecyl sulphate polyacrylamide gel electrophoresis

SSP

:   Species survival program

TMB

:   3,3',5,5'-tetramethylbenzidine

BCA

:   Bicinchoninic acid

BSA

:   Bovine serum albumin

CV

:   Column volume

EEHV

:   Elephant endotheliotropic herpes virus

ELISA

:   Enzyme linked immunosorbent assay

EM

:   *Elephas maximus*

FPLC

:   Fast protein liquid chromatography

gB

:   Glycoprotein B

HPRO

:   Horseradish peroxidase

IMAC

:   Immobilized metal affinity chromatography

IPTG

:   Isopropyl b-D-thiogalactoside

LA

:   *Loxodonta africana*

LB

:   Luria Bertani broth

LPH

:   Limulus polyphemus hemocyanin

Ni-NTA

:   Nickel nitrilotriacetic acid

nm

:   Nanometer

OD

:   Optical density

ORF

:   Open reading frame

PBS

:   Phosphate buffered saline

PCR

:   Polymerase chain reactionPRF, programmed ribosomal frameshifting

PVDF

:   Polyvinylidene difluoride

qPCR

:   Quantative polymerase chain reaction

RBS

:   Ribosomal binding site

SDS-PAGE

:   Sodium dodecyl sulphate polyacrylamide gel electrophoresis

TMB

:   3,3',5,5'-tetramethylbenzidine
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